William Blair Downgrades ZELTIQ Aesthetics (ZLTQ) to Market Perform

Aegis Capital Downgrades ZELTIQ Aesthetics (ZLTQ) to Hold Following Takeover

February 14, 2017 7:54 AM EST

Aegis Capital downgraded ZELTIQ Aesthetics (NASDAQ: ZLTQ) from Buy to Hold after the company agreed to be acquired by Allergan.

For an analyst ratings summary and ratings history on ZELTIQ Aesthetics click here. For more ratings news on ZELTIQ Aesthetics click here.

Shares of ZELTIQ Aesthetics closed at $55.93 yesterday.

... More

Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion

February 13, 2017 8:10 AM EST

By Michael Erman and Natalie Grover

(Reuters) - Botox maker Allergan Plc agreed to pay $2.48 billion in cash for Zeltiq Aesthetics Inc, adding a system that it says helps people slim down by freezing fat away to the company's line-up of aesthetic products.

Allergan said it would benefit from the cross-selling opportunities for consumers of Zeltiq's CoolSculpting System, which uses cooling to kill fat cells, as well as customers of its own facial injectible products.

"Demand for both procedures is high and this is similar to pouring more gas on the fire," Allergan Chief... More

Allergan (AGN) to Acquire ZELTIQ (ZLTQ) for $2.47B

February 13, 2017 8:01 AM EST

Allergan plc (NYSE: AGN) and ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ) announced that they have entered into a definitive agreement under which Allergan has agreed to acquire ZELTIQ for $56.50 per share, or $2.475 billion, subject to customary adjustments.

The acquisition of ZELTIQ is immediately accretive and enhances Allergan's global medical aesthetics portfolio with the addition of ZELTIQ's flagship CoolSculpting® System, the sales leader in the fast-growing cash pay body contouring segment of medical aesthetics. The CoolSculpting System is... More